01
Rabeprazole 20 mg
A proton pump inhibitor that reduces gastric acid secretion by inhibiting the gastric proton pump.
Arovis Pharmaceuticals | Gastroenterology
Control the Acid. Restore the Rhythm.
AroRalev™
Acidity Se Aaraam, AroRalev Ka Naam.
Rabeprazole 20 mg + Levosulpiride 75 mg SR Capsule
AROVIS PHARMACEUTICALS
AroRalev™
Rabeprazole 20 mg + Levosulpiride 75 mg SR Capsule
Caring for life
Product overview
Two Complementary Actions. One Focused Approach.
AroRalev combines acid suppression with prokinetic action in a single sustained-release formulation.
It is positioned within the Arovis gastroenterology portfolio for physician-directed management of acid-related disorders and selected functional gastrointestinal symptoms.
Acid-related gastrointestinal conditions can involve more than gastric acid alone.
AroRalev combines Rabeprazole 20 mg for acid suppression with Levosulpiride 75 mg SR for prokinetic activity. The combination provides a focused approach to acid control and gastrointestinal motility when clinically appropriate.
Formulation science
What’s Inside AroRalev?
02
Levosulpiride 75 mg SR
A sustained-release prokinetic component that supports gastrointestinal motility and gastric emptying.
03
Combined approach
The formulation brings acid control and gastrointestinal motility together.
Mechanism overview
How AroRalev Works
- 01
Acid control
Rabeprazole reduces gastric acid secretion.
- 02
Gastrointestinal motility
Levosulpiride supports gastrointestinal motility and gastric emptying.
- 03
Combined approach
Together, the formulation addresses acid control and motility through complementary pharmacological actions.
Clinical positioning
A Focused Gastroenterology Formulation
Acid control
Helps reduce gastric acid secretion.
Prokinetic action
Supports gastrointestinal motility.
Sustained release
Levosulpiride is provided in an SR formulation.
Complementary action
Brings acid suppression and prokinetic activity together.
Therapeutic focus
Where AroRalev Fits
- Gastroesophageal Reflux Disease (GERD)
- Acid reflux
- Heartburn
- Functional dyspepsia
- Selected gastrointestinal motility-related symptoms
Use only under the direction of a qualified healthcare professional.
Product Information
- Brand
- AroRalev
- Composition
- Rabeprazole 20 mg + Levosulpiride 75 mg SR
- Dosage Form
- Sustained Release Capsule
- Therapeutic Area
- Gastroenterology
- Manufacturer
- Manufactured through qualified pharmaceutical manufacturing partners.
Quality and manufacturing
Quality-Focused Manufacturing
Arovis Pharmaceuticals follows a partner-based manufacturing model.
We work with qualified third-party pharmaceutical manufacturing partners rather than operating our own manufacturing facility.
Where applicable, products are manufactured at facilities meeting relevant WHO-GMP requirements and applicable regulatory standards.
Qualified partner
Quality-focused processes
Responsible practices
Responsible information
Frequently Asked Questions
What is AroRalev?
AroRalev is a combination formulation containing Rabeprazole 20 mg and Levosulpiride 75 mg SR, positioned within the Arovis gastroenterology portfolio.
What does AroRalev contain?
Rabeprazole 20 mg and Levosulpiride 75 mg in sustained-release form.
What therapeutic area does AroRalev belong to?
AroRalev belongs to the Gastroenterology portfolio of Arovis Pharmaceuticals.
Can AroRalev be taken without medical advice?
AroRalev should be used according to the advice of a qualified healthcare professional.
AroRalev™
Focused Gastroenterology Care.
Control the Acid. Restore the Rhythm.
Restricted product information
AroRalev™
Detailed formulation, therapeutic-focus and FAQ information is intended for qualified healthcare professionals or users accessing it under professional medical guidance.
This acknowledgement is not a substitute for legal review of pharmaceutical communication requirements.